Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Company Overview - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases [5] - The company has a multi-stage portfolio powered by a robust R&D engine to address the needs of patients lacking satisfactory treatment options [5] Index Inclusion - Aclaris Therapeutics has been added to the Russell 3000 and Russell 2000 Indexes as of June 30, 2025, following the annual reconstitution of the Russell US Indexes [1] - Membership in the Russell 3000 Index, which includes the 4,000 largest US stocks ranked by market capitalization, ensures automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index [2] Market Impact - The Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies [3] - As of June 2024, approximately $10.6 trillion in assets are benchmarked against the Russell US indexes, indicating significant market influence [3]